High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationKing, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationHealth effects of quercetin: From antioxidant to nutraceutical
Boots, A. W., Haenen, G. R. M. M., & Bast, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.008 · Cited by 2,121
“, 2006), pulmonary fibrosis (Behr et al., 1997; Demedts et al., 2005), diabetes (Hofmann, 1999) and cancer (Bairati et al.”
BackgroundRaghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationPrednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
“T h e Jo u rn al o f E xp er im en ta l M ed ic in e 1340 Mechanisms of pulmonary fibrosis | Wynn in IPF (Demedts et al., 2005).”
BackgroundMoeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
“Those that appear to have a major effect include: Antioxidants (Ambroxol (Pozzi et al., 1989; Pozzi et al., 1987), Niacin (A. Nagai et al., 1994; O'Neill & Giri, 1994; Q. J. Wang, Giri, Hyde, Nakashima, & Javadi, 1990), Taurin (Blaisdell & Giri, 1995; Giri & Wang, 1992; Gurujeyalakshmi, Hollinger, & Giri, 1998; Guruje…”
InfluentialPirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Adult-onset pulmonary fibrosis caused by mutations in telomerase
Tsakiri, K. D., Cronkhite, J. T., Kuan, P. J., Xing, C., Raghu, G., Weissler, J. C., Rosenblatt, R. L., Shay, J. W., & Garcia, C. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701009104 · Cited by 894
Interstitial lung disease guideline
Wells, A. U., Hirani, N., & on behalf of the BTS Interstitial Lung Disease Guideline Group, A. S. O. T. B. T. S. S. O. C. C. (2008) · Thorax · doi:10.1136/thx.2008.101691 · Cited by 866
“This has led to an international randomised double-blind study to assess the effects of NAC in patients in whom a confident or probable diagnosis of IPF was made either on clinicoradiological criteria (82 patients) or clinicoradiological criteria and a lung biopsy (73 patients).(9) All 155 patients analysed in the stu…”
MethodPirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Rushworth, G. F., & Megson, I. L. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.006 · Cited by 719
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
Self-citationEvolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Molecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · Chest · doi:10.1378/chest.06-2568 · Cited by 538
Oxidative stress and pulmonary fibrosis
Cheresh, P., Kim, S.-J., Tulasiram, S., & Kamp, D. W. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.021 · Cited by 530
du Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527
“[4-8] Moreover, several studies have identified change in percent predicted FVC as an independent predictor of mortality in patients with IPF.”
BackgroundSelf-citationEpithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary Fibrosis
Korfei, M., Ruppert, C., Mahavadi, P., Henneke, I., Markart, P., Koch, M., Lang, G., Fink, L., Bohle, R.-M., Seeger, W., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200802-313oc · Cited by 514
“Fourth, as suggested by the results of the Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual (IFIGENIA) trial investigating high-dose N-acetylcysteine application versus placebo (43), increased reactive oxygen species (ROS) generation may contribute to the development of lung fibrosis (44, 45).”
ResultBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401739 · Cited by 505
Antioxidant Therapy: Current Status and Future Prospects
Firuzi, O., Miri, R., Tavakkoli, M., & Saso, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711803414368 · Cited by 468
Oxidative stress and glutathione in TGF-β-mediated fibrogenesis
Liu, R.-M., & Gaston Pravia, K. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.026 · Cited by 469
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Vancheri, C., Failla, M., Crimi, N., & Raghu, G. (2010) · European Respiratory Journal · doi:10.1183/09031936.00077309 · Cited by 464
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454
Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003
Olson, A. L., Swigris, J. J., Lezotte, D. C., Norris, J. M., Wilson, C. G., & Brown, K. K. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-044oc · Cited by 435
“As anticipated for IPF—a disease with short survival and no effective therapy (17, 18)—the mortality rates we found mirror the recently described increasing incidence (19–21).”
ResultLai, Z., Hanczko, R., Bonilla, E., Caza, T. N., Clair, B., Bartos, A., Miklossy, G., Jimah, J., Doherty, E., Tily, H., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34502 · Cited by 428
Classification and Natural History of the Idiopathic Interstitial Pneumonias
Kim, D. S., Collard, H. R., & King, T. E. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-005tk · Cited by 431
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
Meltzer, E. B., & Noble, P. W. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-8 · Cited by 407
“This pilot study prompted a large, randomized, double-blinded study of 182 IPF patients to compare the efficacy of a regimen that included prednisone, azathioprine and NAC to a regimen of only prednisone and azathioprine [23].”
N -acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517901 · Cited by 413
“NAC has a benign side effect profile that does not differ significantly from placebo in most clinical trials [10,11,21,37,70] .”
BackgroundSix-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis
Lederer, D. J., Arcasoy, S. M., Wilt, J. S., D'Ovidio, F., Sonett, J. R., & Kawut, S. M. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-520oc · Cited by 402
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 382
“The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study [110], published in 2005 suggested that the addition of N-acetylcysteine (NAC), an anti-oxidant compound, to this combination would help to preserve lung function.”
BackgroundImatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Zappala, C. J., Latsi, P. I., Nicholson, A. G., Colby, T. V., Cramer, D., Renzoni, E. A., Hansell, D. M., du Bois, R. M., & Wells, A. U. (2010) · European Respiratory Journal · doi:10.1183/09031936.00155108 · Cited by 372
Self-citationTreatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
Self-citationOxidative stress in the pathology and treatment of systemic lupus erythematosus
Perl, A. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.147 · Cited by 358
The pathogenesis of pulmonary fibrosis: a moving target
Wuyts, W. A., Agostini, C., Antoniou, K. M., Bouros, D., Chambers, R. C., Cottin, V., Egan, J. J., Lambrecht, B. N., Lories, R., Parfrey, H., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00073012 · Cited by 356
Self-citationFibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT?
Radisky, D. C., Kenny, P. A., & Bissell, M. J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21186 · Cited by 344
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases
Perl, A. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.172 · Cited by 332
TGF-β signaling in tissue fibrosis: Redox controls, target genes and therapeutic opportunities
Samarakoon, R., Overstreet, J. M., & Higgins, P. J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.10.003 · Cited by 332
Reactive oxygen species and fibrosis: further evidence of a significant liaison
Richter, K., & Kietzmann, T. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2445-3 · Cited by 322
“Multicentre trials among patients suffering from idiopathic lung fibrosis have shown that antioxidant treatment has no or only a modestly beneficial effect (Demedts et al. 2005; Day 2008; Idiopathic Pulmonary Fibrosis Clinical Research Network et al. 2014).”
BackgroundScotton, C. J., Krupiczojc, M. A., Königshoff, M., Mercer, P. F., Lee, Y. C. G., Kaminski, N., Morser, J., Post, J. M., Maher, T. M., Nicholson, A. G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci33288 · Cited by 319
Self-citationThe Role of Inflammation in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Bringardner, B. D., Baran, C. P., Eubank, T. D., & Marsh, C. B. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1897 · Cited by 311
“In human disease, NAC has some benefit in the treatment of IPF (36), implying a potential role of oxidants and free radicals in the pathophysiology of native IPF.”
Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
NISHIYAMA, O., KONDOH, Y., KIMURA, T., KATO, K., KATAOKA, K., OGAWA, T., WATANABE, F., ARIZONO, S., NISHIMURA, K., & TANIGUCHI, H. (2008) · Respirology · doi:10.1111/j.1440-1843.2007.01205.x · Cited by 316
Oxidative Stress in Pulmonary Fibrosis
Otoupalova, E., Smith, S., Cheng, G., & Thannickal, V. J. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190017 · Cited by 262
Baseline BAL Neutrophilia Predicts Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., Schwarz, M. I., Ix, J. H., Kervitsky, A., & King, T. E. (2008) · Chest · doi:10.1378/chest.07-1948 · Cited by 302
Raghu, G., Berk, M., Campochiaro, P. A., Jaeschke, H., Marenzi, G., Richeldi, L., Wen, F.-Q., Nicoletti, F., & Calverley, P. M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666201230144109 · Cited by 280
“CONFLICT OF INTEREST Ganesh Raghu reports consultation services to Zambon Pharma SpA and research grant support from National Institutes of Health, Bethesda, Maryland, USA for IPF studies with NAC.”
BackgroundInfluentialA key role for nox4 in epithelial cell death during development of lung fibrosis
Carnesecchi, S., Deffert, C., Donati, Y., Basset, O., Hinz, B., Preynat-Seauve, O., Guichard, C., Arbiser, J. L., Banfi, B., Pache, J.-C., et al. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3829 · Cited by 290
“Reactive oxygen species (ROS) have been involved in the disease, although an antioxidant treatment used in a multicenter patient trial showed modest beneficial effects (11, 12, 18).”
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., & the MUSIC Study Group (2013) · European Respiratory Journal · doi:10.1183/09031936.00104612 · Cited by 277
Self-citationThe pathogenesis of idiopathic pulmonary fibrosis
Coward, W. R., Saini, G., & Jenkins, G. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810379801 · Cited by 272
“Recently, it has been proposed that N-acetylcysteine, which, when given with prednisolone and azathioprine improves the clinical course of IPF [Demedts et al. 2005], may act by inhibiting TGF-b-induced EMT [Felton et al. 2009].”
BackgroundN-acetylcysteine: multiple clinical applications.
Millea, P. J. (2009) · PubMed · Cited by 271
Pulmonary hypertension in interstitial lung disease: Fig. 1—
Behr, J., & Ryu, J. H. (2008) · European Respiratory Journal · doi:10.1183/09031936.00171307 · Cited by 263
Self-citationQuercetin reduces markers of oxidative stress and inflammation in sarcoidosis
Boots, A. W., Drent, M., de Boer, V. C. J., Bast, A., & Haenen, G. R. M. M. (2011) · Clinical Nutrition · doi:10.1016/j.clnu.2011.01.010 · Cited by 247
Strategies for treating idiopathic pulmonary fibrosis
du Bois, R. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2958 · Cited by 251
“In the IFIGENIA (Idiopathic Pulmonary Fibrosis International Group Exploring N -acetylcysteine I Annual) study — an international randomized, double-blind, placebo-controlled add-on study — patients were allocated to receive either oral N -acetylcysteine or placeb”
MethodRole of glutathione in immunity and inflammation in the lung
Ghezzi, P. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s15618 · Cited by 244
“22”
Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials
Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., Martinez, F. J., & Brown, K. K. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0006pp · Cited by 242
Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences
Richter, K., Konzack, A., Pihlajaniemi, T., Heljasvaara, R., & Kietzmann, T. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.015 · Cited by 238
Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis
Farkas, L., Gauldie, J., Voelkel, N. F., & Kolb, M. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0365tr · Cited by 237
Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M. A., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01592-2016 · Cited by 233
Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis
Kliment, C. R., & Oury, T. D. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.04.036 · Cited by 234
Ahluwalia, N., Shea, B. S., & Tager, A. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0509pp · Cited by 235
Identification of Early Interstitial Lung Disease in Smokers from the COPDGene Study
Washko, G. R., Lynch, D. A., Matsuoka, S., Ross, J. C., Umeoka, S., Diaz, A., Sciurba, F. C., Hunninghake, G. M., San José Estépar, R., Silverman, E. K., et al. (2010) · Academic Radiology · doi:10.1016/j.acra.2009.07.016 · Cited by 232
“48 unclear, if initation of therapy at the earliest stages of disease would alter its clinical course (4,5).”
BackgroundThe Processes and Mechanisms of Cardiac and Pulmonary Fibrosis
Murtha, L. A., Schuliga, M. J., Mabotuwana, N. S., Hardy, S. A., Waters, D. W., Burgess, J. K., Knight, D. A., & Boyle, A. J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00777 · Cited by 229
“Whilst the anti-oxidant, N -acetylcysteine combined with glucocorticoids decelerates loss of lung function for IPF patients, there is no effect on mortality rates (Demedts et al., 2005).”
BackgroundTargeting the Redox Balance in Inflammatory Skin Conditions
Wagener, F., Carels, C., & Lundvig, D. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14059126 · Cited by 217
“For instance, the antioxidant compound N-acetyl cysteine (NAC) has been successfully used in the treatment of idiopathic pulmonary fibrosis [316–319], an inflammatory condition with etiology linked”
MethodInterstitial lung disease in connective tissue disease—mechanisms and management
Wells, A. U., & Denton, C. P. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.149 · Cited by 211
S-Nitrosothiol Signaling in Respiratory Biology
Gaston, B., Singel, D., Doctor, A., & Stamler, J. S. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1584pp · Cited by 215
“are mediated predominantly by S-nitrosylation (8, 11, 41 , 54, 55).”
BackgroundSerum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., McCormack, F. X., Ix, J. H., Kervitsky, A., Schwarz, M. I., & King, T. E. (2009) · Chest · doi:10.1378/chest.08-2209 · Cited by 209
Walters, D. M., Cho, H.-Y., & Kleeberger, S. R. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1901 · Cited by 206
Baughman, R. P., Costabel, U., & du Bois, R. M. (2008) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2008.03.012 · Cited by 206
Self-citationNovel therapeutic approaches for pulmonary fibrosis
Datta, A., Scotton, C. J., & Chambers, R. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01247.x · Cited by 202
“, 1991) has been translated, to some degree at least, into a clinical benefit in IPF (Demedts et al., 2005).”
BackgroundMMP expression and abnormal lung permeability are important determinants of outcome in IPF
McKeown, S., Richter, A. G., O'Kane, C., McAuley, D. F., & Thickett, D. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00060708 · Cited by 200
Herzog, E. L., Mathur, A., Tager, A. M., Feghali‐Bostwick, C., Schneider, F., & Varga, J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38702 · Cited by 193
“placebo AZA prednisone Demedts et al, 2005 (74) Randomized, placebo-controlled trial; 9% difference in FVC between groups at 12 months”
BackgroundHigh-Dose N-Acetylcysteine in Stable COPD
Tse, H. N., Raiteri, L., Wong, K. Y., Yee, K. S., Ng, L. Y., Wai, K. Y., Loo, C. K., & Chan, M. H. (2013) · Chest · doi:10.1378/chest.12-2357 · Cited by 187
Hansell, D. M., Goldin, J. G., King, T. E., Lynch, D. A., Richeldi, L., & Wells, A. U. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00096-x · Cited by 189
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
Richeldi, L., Ryerson, C. J., Lee, J. S., Wolters, P. J., Koth, L. L., Ley, B., Elicker, B. M., Jones, K. D., King, T. E., Ryu, J. H., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201184 · Cited by 185
Dyskeratosis congenita, stem cells and telomeres
Kirwan, M., & Dokal, I. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.01.010 · Cited by 180
“IPF patients have shown some response to antioxidant treatment including increased epithelial lung fluid glutathione levels and mildly improved lung function tests [89-92], suggesting that prevention of cell damage or loss due to oxidative stress can improve the prognosis.”
Backgroundde Lauretis, A., Veeraraghavan, S., & Renzoni, E. (2011) · Chronic Respiratory Disease · doi:10.1177/1479972310393758 · Cited by 182
Castelino, F. V., & Varga, J. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3097 · Cited by 182
“In IPF, N-acetylcysteine added to a regimen of prednisone and azathioprine slowed deterioration of the FVC and diff using capacity for carbon monoxide at 12 months [67].”
Raghu, G., & Selman, M. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2044ed · Cited by 185
The immunology of fibrosis: innate and adaptive responses
Wick, G., Backovic, A., Rabensteiner, E., Plank, N., Schwentner, C., & Sgonc, R. (2010) · Trends in Immunology · doi:10.1016/j.it.2009.12.001 · Cited by 179
“Several mutually non-exclusive hypotheses have been proposed, including infection, reaction to altered self, overproduction of reactive oxygen species (ROS) and nitric oxide (NO), or mechanical stress [1-4] (Box 1, Figure 3).”
BackgroundDiagnosis and management of interstitial lung disease
Meyer, K. C. (2014) · Translational Respiratory Medicine · doi:10.1186/2213-0802-2-4 · Cited by 177
Current Perspectives on the Treatment of Idiopathic Pulmonary Fibrosis
Walter, N., Collard, H. R., & King, T. E. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200602-016tk · Cited by 174
“A recent multicenter randomized trial, the IFIGENIA study, tested acetylcysteine with azathioprine and high-dose corticosteroids versus azathioprine and high-dose corticosteroids alone in a population with rigorously established IPF (45).”
MethodResultInfluentialAdverse Gastrointestinal Effects of Arginine and Related Amino Acids
Grimble, G. K. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.6.1693s · Cited by 176
Rogliani, P., Calzetta, L., Cavalli, F., Matera, M. G., & Cazzola, M. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.07.009 · Cited by 168
“In fact low-doses of corticosteroids were allowed in all the studies on nintedanib [40, 41], in one study on pirfenidone [42] and in two studies on NAC [35, 43].”
BackgroundPulmonary Function Testing in Idiopathic Interstitial Pneumonias
Martinez, F. J., & Flaherty, K. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200602-022tk · Cited by 169
Non-steroid agents for idiopathic pulmonary fibrosis
Spagnolo, P., Del Giovane, C., Luppi, F., Cerri, S., Balduzzi, S., Walters, E. H., D'Amico, R., & Richeldi, L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003134.pub2 · Cited by 163
Fibrogenesis of Parenchymal Organs
Kisseleva, T., & Brenner, D. A. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200711-168dr · Cited by 161
“Acetylcysteine, a precursor of the major antioxidant glutathione, was shown to restore depleted pulmonary glutathione levels and to improve lung function in patients with fibrotic lung disease ( 32 , 33).”
BackgroundSubclinical Interstitial Lung Disease: Why You Should Care
Doyle, T. J., Hunninghake, G. M., & Rosas, I. O. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1420pp · Cited by 164
Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis
Thomeer, M., Demedts, M., Behr, J., Buhl, R., Costabel, U., Flower, C. D. R., Verschakelen, J., Laurent, F., Nicholson, A. G., Verbeken, E. K., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00063706 · Cited by 157
“Given that idiopathic pulmonary fibrosis has such a poor prognosis [2] in relation to other forms of idiopathic interstitial pneumonia [3], it was concluded that the use of independent high-resolution computed tomography and histology panels to ensure accurate diagnosis of idiopathic pulmonary fibrosis, as performed i…”
BackgroundSelf-citationCombination therapy: the future of management for idiopathic pulmonary fibrosis?
Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70232-2 · Cited by 150
Self-citationOxidative Stress, Plasminogen Activator Inhibitor 1, and Lung Fibrosis
Liu, R.-M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1903 · Cited by 150
“Such an imbalance between oxidants and antioxidants is most likely to contribute to the pathogenesis of IPF and CF, as antioxidant treatment has been shown to be able to improve the clinical manifestations (15, 52, 82, 88, 230).”
Santus, P., Corsico, A. G., Solidoro, P., Braido, F., Marco, F. D., & Scichilone, N. (2014) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2014.898040 · Cited by 169
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets
Liu, Y.-M., Nepali, K., & Liou, J.-P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00935 · Cited by 147
Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Saito, S., Alkhatib, A., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.62 · Cited by 148
Behr, J., Bendstrup, E., Crestani, B., Günther, A., Olschewski, H., Sköld, C. M., Wells, A., Wuyts, W., Koschel, D., Kreuter, M., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30044-3 · Cited by 146
Self-citationIdiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis
Horowitz, J., & Thannickal, V. (2006) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2006-957332 · Cited by 146
Antioxidants as Potential Therapeutics for Lung Fibrosis
Day, B. J. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1916 · Cited by 138
“A more recent multicenter randomized trial further investigated the possible benefits of oral NAC therapy in combination with azathioprine and high-dose corticosteroids in a larger cohort of IPF subjects (60).”
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.